BTIG Research Reiterates Buy Rating for Novogen (NASDAQ:KZIA)

Novogen (NASDAQ:KZIA)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a research note issued on Wednesday,Benzinga reports. They currently have a $34.00 target price on the stock. BTIG Research’s price target points to a potential upside of 159.15% from the stock’s current price.

Several other research firms also recently issued reports on KZIA. Lake Street Capital initiated coverage on Novogen in a report on Thursday, June 11th. They issued a “buy” rating and a $32.00 price objective on the stock. Laidlaw initiated coverage on Novogen in a report on Wednesday, April 15th. They set a “buy” rating and a $25.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research report on Tuesday, April 21st. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.80.

Novogen Stock Performance

NASDAQ:KZIA opened at $13.12 on Wednesday. The stock’s fifty day moving average is $13.19 and its two-hundred day moving average is $9.76. Novogen has a 52 week low of $4.86 and a 52 week high of $17.40.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.